This dual-action approach is why Tirzepatide often leads to better weight loss results, with fewer symptoms
Lose up to 20%* of your body weight with this simple, weekly GLP-1+GIP tailored just to you
Clinical trials have demonstrated its safety and effectiveness, and the FDA has approved it for weight management
Tirzepatide Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist sometimes called a twincretin. GIP is a second gut hormone involved in insulin secretion, fat storage regulation, and energy metabolism
Patients should undergo comprehensive cardiovascular assessment before initiating Zepbound, including blood pressure measurement, lipid panel, hemoglobin A1c (if diabetic or prediabetic), and electrocardiogram if clinically indicated